Table of Contents

By 2035, more than half the world’s population—over four billion people—could be classified as overweight or obese, according to the World Obesity Federation’s 2023 Atlas. This prediction isn’t just about obesity alone. It also highlights the growing health risks linked to obesity, such as heart disease, diabetes, stroke, and even pregnancy complications.

Several FDA-approved medications, including orlistat, phentermine-topiramate, and semaglutide, are already in use to support weight loss. Among them, tirzepatide has recently shown significant promise, with clinical trials reporting an average weight loss of 20.2%. Now, researchers are turning their attention to retatrutide, a new drug that could become another option for managing obesity.

In this article, we’ll examine what retatrutide offers, what early studies reveal, and its potential for treating obesity.

Key Takeaways

  • Retatrutide activates three receptors—GLP-1, GIP, and glucagon—simultaneously, offering comprehensive metabolic benefits.
  • Early trials showed significant weight loss (up to 24.2% body weight at 48 weeks) and liver fat reduction (up to 82.4%) in participants with obesity or related conditions.
  • Retatrutide improved HbA1c levels and facilitated weight loss in individuals with type 2 diabetes, with effects noted even at lower doses.
  • Common side effects include mild-to-moderate gastrointestinal symptoms, similar to existing GLP-1 agonists like semaglutide.
  • Retatrutide is in Phase 3 trials, with potential FDA approval and availability expected by late 2025 or early 2026 if results are favorable.
  • Retatrutide is aimed at individuals with obesity, type 2 diabetes, or metabolic disorders, but it may not be suitable for those with type 1 diabetes or severe gastrointestinal issues.

What is Retatrutide?

Retatrutide is a novel investigational medication being developed by Eli Lilly and Company for its potential to treat conditions such as obesity, type 2 diabetes, and potentially other metabolic disorders. It belongs to a new class of drugs called multi-receptor agonists, targeting multiple hormone pathways to achieve significant therapeutic effects.

How Does Retatrutide Work?

Retatrutide is a triple agonist, meaning it simultaneously activates three different receptors involved in regulating energy balance and glucose metabolism. These receptors include:

1. Glucagon-like peptide-1 receptor (GLP-1R)

GLP-1 receptors are found in several key areas of the body, including the pancreas, brain, and stomach. Here’s what happens when these receptors are activated:

    • In the pancreas: After you eat, blood sugar levels naturally rise. Insulin, a hormone produced by the pancreas, helps bring these levels back to a healthy range. Activation of GLP-1 receptors signals the pancreas to release insulin, especially after meals when blood sugar is high. It also prevents the liver from releasing unnecessary glucose into the bloodstream, further stabilizing blood sugar levels.
    • In the brain: It signals the brain’s hunger centers to let you know you’re full. It also prolongs feelings of satisfaction, reducing the urge to snack or overeat. This is particularly beneficial for individuals prone to binge eating or struggling with portion control.
    • In the stomach: It slows gastric emptying, which is how quickly food moves from the stomach into the intestines. Carbohydrates are broken down into glucose and absorbed in the small intestine. If this happens too quickly, it can cause sharp spikes in blood sugar. By keeping food in the stomach longer, GLP-1 receptor activation promotes feelings of fullness (satiety), reduces hunger, and prevents rapid post-meal blood sugar increases.

Market Trends

In 2023, Novo Nordisk’s semaglutide, marketed as Ozempic, Wegovy, and Rybelsus, dominated the GLP-1 market, accounting for over 88% of all new prescriptions.

2. Glucose-dependent insulinotropic polypeptide receptor (GIPR)

GIPR complements the effects of GLP-1 by influencing insulin release in response to rising blood sugar levels. But that’s not all. Researchers have discovered its significant role in how the body processes and stores fat.

According to experts, GIP helps your body use fat more efficiently, preventing it from “spilling over” into places it doesn’t belong, like your liver, muscles, heart, or pancreas. This kind of fat buildup, called ectopic fat, is linked to serious health issues, such as:

    • Insulin resistance
    • Fatty liver disease
    • Heart problems

If you have type 2 diabetes, this is especially important because these conditions are often connected. They tend to worsen each other, creating a cycle that can make managing your health even more challenging.

Tirzepatide (under the brand names Mounjaro and Zepbound), a dual GIPR and GLP-1 agonist, has shown remarkable results in managing both diabetes and obesity, often surpassing the effects of GLP-1 agonists alone.

Medical Fact

Retatrutide is nearly 9 times more effective than the natural GIP hormone at activating the GIP receptor.

3. Glucagon receptor (GCGR)

Glucagon is a hormone produced by the pancreas that binds to the glucagon receptor (GCGR) in liver cells. When activated, GCGR signals the liver to:

    • Break down a type of stored sugar called glycogen into glucose
    • Release glucose into the bloodstream

GCGR activation also helps your body burn fat and protein for energy. These processes are known as:

    • Lipolysis: Breaking down fat
    • Gluconeogenesis: Making new glucose from other sources like protein

It’s especially helpful during fasting, exercise, or times when your diet doesn’t provide enough calories. Through its mechanisms, the glucagon receptor helps keep your blood sugar steady and prevents you from running out of energy.

By combining all these effects, retatrutide offers a promising approach to managing weight, type 2 diabetes, and other metabolic conditions.

Is Retatrutide Safe and Effective?

scientists in lab

Early trials of retatrutide resulted in significant improvements. For example:

    • Weight reduction in obese adults without diabetes: At 24 weeks, the retatrutide group achieved an average weight reduction of up to 17.5% (approximately 41.2 lbs). By 48 weeks, this increased to a mean weight loss of up to 24.2% (about 57.8 lbs).
    • Liver fat reduction: In participants with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease or NAFLD, retatrutide reduced liver fat levels by up to 82.4%. In contrast, the placebo group showed virtually no change, with a 0.3% increase in liver fat.

Additionally, up to 86% achieved normal liver fat levels (less than 5%). None of the participants in the placebo group reached this benchmark.

    • Glycemic control and weight loss in adults with type 2 diabetes: At 24 weeks, 12 mg retatrutide reduced HbA1c (a key marker of blood sugar control) by 2.02%. At 36 weeks, participants on retatrutide 12 mg lost an average of 16.94% of their body weight. Even lower doses, like 4 mg, resulted in noticeable weight loss (7.92% to 10.37%).

More importantly, the safety profile of retatrutide was similar to GLP-1 receptor agonists, with mild-to-moderate gastrointestinal side effects like:

    • nausea
    • diarrhea
    • constipation
    • vomiting

When Will Retatrutide Be Available?

Pharmacy Shelf

Retatrutide is currently undergoing Phase 3 clinical trials (TRIUMPH studies). These trials are essential to evaluate the drug’s safety and effectiveness. Even if the drug works, the potential risks (e.g., severe side effects or long-term health issues) must not outweigh its benefits.

If the outcomes are favorable, Eli Lilly will likely submit a New Drug Application to the US Food and Drug Administration (FDA).

Considering the typical timelines for clinical trials and regulatory review, retatrutide could potentially receive FDA approval and become available to the public by late 2025 or early 2026. These timelines are subject to change based on the results of ongoing trials and the regulatory process.

What Happens If Results Are Not Favorable?

The drug may be shelved, discontinued, or sent back for additional research or modifications. Even if one indication (e.g., obesity) fails, the drug could still be explored for other uses where it shows promise.

Who Would Retatrutide Be For?

Retatrutide could be a suitable treatment option for people facing the following conditions:

    • Type 2 diabetes
    • Obesity or overweight
    • Obesity-related complications, such as NAFLD, sleep apnea, and joint pain or mobility issues
    • Metabolic disorders, such as a combination of high blood sugar, abdominal fat, high cholesterol, and high blood pressure

Just like other medications, retatrutide also has contraindications. It might not be appropriate for people with:

    • Type 1 diabetes
    • A history of severe gastrointestinal issues due to side effects

Final Thoughts

Retatrutide is a new drug being studied by Eli Lilly, the same company behind popular medications Mounjaro and Zepbound. It has shown remarkable potential in clinical trials. Participants experienced significant weight loss, improved liver health, and better glycemic control, all while maintaining a safety profile similar to existing GLP-1 receptor agonists. However, its future depends on the trial outcomes and regulatory approval.

Frequently Asked Questions

Retatrutide is not yet available for public use as it is still undergoing clinical trials. If approved, it will require a prescription and may initially be accessible through specialty pharmacies.

Clinical trials for retatrutide have explored various doses, including 1 mg, 4 mg, 8 mg, and 12 mg, administered once weekly. Final approved dosages will depend on ongoing trial outcomes and regulatory decisions.

Both retatrutide and tirzepatide target metabolic disorders like obesity and type 2 diabetes. Retatrutide may offer broader benefits by activating three receptors, whereas tirzepatide works on two. Comparative effectiveness depends on individual health conditions and further trial results.

Semaglutide targets only the GLP-1 receptor, while retatrutide activates GLP-1, GIP, and glucagon receptors. Retatrutide’s triple-agonist mechanism may provide superior weight loss and metabolic benefits, but direct comparisons will require more research.

Retatrutide may also help manage conditions related to metabolic health, such as sleep apnea and cardiovascular risks.

Insurance coverage for retatrutide will depend on the drug’s approved indications and pricing. Once available, it’s likely to be included in coverage for obesity or diabetes treatment plans.

Currently, doctors cannot prescribe retatrutide because it is still in the clinical trial phase and has not yet received FDA approval. Once approved, it will be available by prescription for eligible patients.

Long-term safety data for retatrutide is not yet available as it is still undergoing clinical trials. Early results suggest a safety profile similar to existing GLP-1 agonists, but further research is needed.

The safety and efficacy of combining retatrutide with other weight-loss medications have not been studied. This will likely be clarified after approval and further research.

Related Articles

Sources

Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–Hormone-Receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/nejmoa2301972

Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., Haupt, A., & Hartman, M. L. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 30(7), 2037–2048. https://doi.org/10.1038/s41591-024-03018-2

Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., & Coskun, T. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet, 402(10401), 529–544. https://doi.org/10.1016/s0140-6736(23)01053-x

Eli Lilly. (2023). Lilly’s phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight. Lilly Investors. Retrieved from https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-retatrutide-results-published-new-england-journal

Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020). How may GIP enhance the therapeutic efficacy of GLP-1? Trends in Endocrinology and Metabolism, 31(6), 410–421. https://doi.org/10.1016/j.tem.2020.02.006

Naeem, M., Imran, L., & Banatwala, U. E. S. S. (2024). Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence. Health Science Reports, 7(2). https://doi.org/10.1002/hsr2.1864